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Abstract
Despite advances in the diagnosis and treatment of Clostridium difficile infection (CDI),
the prevention of CDI, particularly in the inpatient hospital setting, remains a challenge.
Clostridium difﬁcile now rivals methicillin-resistant staphylococcus aureus (MRSA) as
the most common pathogen to cause hospital acquired infections (HAI) in the United
States. Hospitalized patients are considered to be especially high risk for CDI, and
among inpatient cases, antibiotic treatment, especially with Fluoroquinolones has been an
almost universal factor in the development of CDIs. One preventative measure that is
incontinently used in the prevention of CDI is oral probiotics. Probiotic consumption is
reported to exert a myriad of beneficial effects including enhanced immune response,
balancing of colonic microbiota, treatment of diarrhea associated with travel and
antibiotic therapy, control of rotavirus and clostridium difficile induced colitis. The
American College of Gastroenterology recognizes the role of probiotics and included
probiotics as a level B recommendation for the treatment of CDI. It has been
hypothesized that the use of probiotics, as an adjunctive therapy in patients receiving
antibiotics, may provide a key intervention in reducing primary CDI. The purpose of this
study was to conduct a retrospective chart review to explore healthcare providers
prescribing trends regarding Fluoroquinolone antibiotics and adjunctive probiotics in
patients with hospital acquired CDI. The Synergy model was used to guide the study.
Results indicated that probiotics are not frequently prescribed for hospitalized patients on
Fluoroquinolones and when they are it is with inconsistency. Additional research is
recommended to further assess the use of probiotics in conjunction with other classes of
commonly used antibiotics; this study solely looked at Fluoroquinolones.
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THE USE OF PROBIOTICS IN THE PREVENTION OF CLOSTRIDIUM DIFFICILE
INFECTION
Background/Statement of the Problem
Despite advances in the diagnosis and treatment of Clostridium difficile infection
(CDI), the prevention of CDI, particularly in the inpatient hospital setting, remains a
challenge. In recent years, both the incidence and severity of (CDI) have increased,
accompanied by an associated rise in mortality (Centers for Disease Control [CDC],
2015b). CDI is a serious health care associated infection and a growing health care
problem. “Hospital-acquired infections (HAI) are a major concern for hospitals across the
country and C. difficile is among the most dangerous,” says principal investigator
Leonard Mermel, D.O., Medical Director of the department of epidemiology and
infection control at Rhode Island Hospital (Jefferson et al., 2013). Clostridium difﬁcile
now rivals methicillin-resistant staphylococcus aureus (MRSA) as the most common
pathogen to cause hospital acquired infections (HAI) in the United States (Dubberke et
al., 2014). A statistic from the 2014 update of Strategies to Prevent Clostridium Difficile
Infections in Acute Care Hospital, published by the Society for Healthcare Epidemiology
of America, is that patients who received ICD 9 codes for the discharge diagnosis of
clostridium difficile infection more than doubled from 2000 to 2009 (Dubberke et al.). In
2011, a point prevalence survey of heath care associated infections was performed; from
183 hospitals and 10 states, 11,282 patients were randomly selected. Of those 11,282,
4.0% had one or more HAI, and Clostridium difficile was the most commonly identified
pathogen, accounting for 12% of all HAIs (Dubberke et al.). According to the CDC, an
estimated half a million CDI infections were diagnosed in the United States during 2011
(CDC, 2015b). Approximately 83,000 of the patients who developed CDI experienced
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at least one recurrence and 29,000 of these patients died within 30 days of the initial
diagnosis (CDC, 2015a).
The rise in CDI rates has been recognized as an issue here in Rhode Island and
steadily continues to gain national recognition. Based on 2013 data published on the CDC
website, Rhode Island is among ten other states whose CDI rates have exceeded the
national average (CDC, 2015a). The rate of CDI in Rhode Island increased more than
three fold over the past decade going from 5.21 per 1,000 discharges in 2002 to 18.87 per
1,000 in 2012, outpacing national trends and neighboring states (Jiang, et al., 2014). In
the first quarter of 2013 Rhode Island ranked 1st among the 50 states and Washington
D.C. (Jiang et al.).
C. difficile infection is the major identifiable cause of antibiotic-associated
diarrhea and is responsible for 15–25 percent of all cases, with a marked increase in the
incidence of CDI since the turn of the 21st century (Bartlett & Gerding, 2008). The
reemergence of CDI, coupled with an increasingly vulnerable healthcare population, has
resulted in more frequent medical and surgical complications, added health care costs,
and greater mortality (DePestel & Aronoff, 2013). Hospitalized patients are considered to
be especially high risk for CDI, and among inpatient cases, antibiotic treatment has been
an almost universal factor in the development of CDIs (DePestel & Aronoff). This makes
hospitalized individuals who are receiving antibiotic the most susceptible. According to
the CDC, more than half of all hospitalized patients will get an antibiotic at some point
during their hospital stay (CDC, 2015b).
Fluoroquinolone resistance appears to have been a critical factor in the
worldwide spread of the pathogen, including its persistence in the hospital environment
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(Kenneley, 2014). Due to the fact that CDI has received a lot of media and medical
attention over the past several years, many hospitals have implemented strict protocols
and preventative bundles to help reduce occurrence rates. Due to the nature of this
resilient organism, all evidence based preventative measures should be considered. One
preventative measure that is incontinently used in the prevention of CDI is oral
probiotics.
Probiotic consumption is reported to exert a myriad of beneficial effects including
enhanced immune response, balancing of colonic microbiota, treatment of diarrhea
associated with travel and antibiotic therapy, control of rotavirus and clostridium difficile
induced colitis. Probiotic bacteria attach to enterocytes and thus inhibit the binding of
enteric pathogens to the intestinal mucosa by production of inhibitory substances.
Emerging evidence has revealed that prevention of gastrointestinal tract colonization by a
variety of pathogens such as clostridium difficile is a primary mechanism of beneficial
effects mediated by probiotics. (Kaur, Chopra, & Saini, 2001).
The American College of Gastroenterology recognizes the role of probiotics and
included probiotics as a level B recommendation for the treatment of CDI (Avadhani &
Miley, 2011). It has been hypothesized that the use of probiotics, as an adjunctive therapy
in patients receiving antibiotics, may provide a key intervention in reducing primary CDI
(Evans & Johnson, 2015)
Based on the compelling evidence regarding the use of oral probiotics as an
adjunctive therapy it is necessary to explore if in fact providers are prescribing probiotics
to patients receiving antibiotic therapy. More specifically an important question is if
providers are prescribing to patients who are hospitalized and receiving Fluoroquinolone
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antibiotic. Therefore, the purpose of this research was to explore healthcare providers
prescribing trends regarding Fluoroquinolone antibiotics and adjunctive probiotics use.
Review of literature will be discussed next.
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Literature Review
To conduct a review of literature the following databases were searched:
MEDLINE, PubMed, Ovid, CDC and World Health Organization. The terms,
Clostridium difficile infection (CDI), CDI and Probiotics, prevention of CDI, methods of
Prevention in CDI, what is a probiotic, physician use of probiotics, and fluoroquinolones
causing CDI were used. The literature review includes the following subsections:
clostridium difficile infection and contributing factors; probiotic definition and action;
probiotics: usage as a preventative measure of CDI; fluoroquinolones and CDI;
prescribers influence in the use of probiotics.
Clostridium Difficile Infection (CDI) and Contributing Factors
A nosocomial infection — also called “hospital acquired infection” can be
defined as an infection acquired in hospital by a patient who was admitted for a reason
other than that infection (World Health Organization, 2002). Clostridium difficile is a
Gram-positive, spore-forming, anaerobic bacterium that when ingested can cause CDI
(CDC, 2015a). Clostridium difficile infection symptoms include varying severity of
diarrhea as well as abdominal pain, cramping and possible fever. Clostridium difficile is
shed in feces and in order for a person to develop CDI they must be infected with a strain
of C. difficile capable of making toxins in the colon. Any surface, device, or material
(e.g., toilets, bathing tubs, and electronic rectal thermometers) that becomes contaminated
with feces may serve as a reservoir for the Clostridium difficile spores (McDonald &
Stokowski, 2012). Clostridium difficile spores are transferred to patients mainly via the
hands of healthcare personnel who have touched a contaminated surface or item.
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Clostridium difficile can live for long periods of time on surfaces (CDC, 2015a).
Additionally, unnecessary or excessive antibiotic use combined with poor infection
control practices may increase the spread of C. difficile within a facility and across
facilities (McDonald & Stokowski, 2012). Touching a patient who is colonized with CDI
or interacting in the environment of a patient colonized with CDI can lead to infection
(CDC, 2015a). The major difference among the three organisms is that C.difficile forms
spores whereas the other infectious organisms do not. The formation of spores poses
unique challenges for hand hygiene and environmental disinfection practices, since C.
difficile spores are resistant to the bactericidal effects of alcohol and the most commonly
used hospital disinfectants (Dubberke et al, 2014).
As of January 2013, the Centers for Medicare & Medicaid Services (CMS)
require all acute care hospitals participating in their Inpatient Prospective Payment
System to report any laboratory-identified CDI using the National Health Safety Network
(NHSN). The NHSN has defined healthcare facility onset, also phrased health care
facility associated CDI, as CDI symptom onset more than 3 days after admission to a
healthcare facility, with day of admission being day one (Sievert et al., 2013).
Probiotics: Definition and Actions
In an expert consensus document published by the International Scientific
Association for Probiotics and Prebiotics in 2013, the Food and Agriculture Organization
of the United Nations and World Health Organization defined probiotics as, “live
microorganisms which when administered in adequate amounts confer a health benefit on
the host” (p.506). Probiotics are active living microorganisms that have a defined health
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benefit – either therapeutic or preventative when ingested in sufficient quantity
(Heiberger, Hellwig, & Ladwig, 2014). Probiotics are bacteria similar to the beneficial
microbes naturally found in the human gut and are used to replace or increase an
individual’s microflora (Merenstein, 2012). Several mechanisms have been proposed to
explain the actions of probiotics, but in most cases the exact mechanism of action is not
fully understood and it is likely that a number of mechanisms are working simultaneously
(Heiberger, Hellwig, & Ladwig 2014). Probiotics protect intestinal epithelial cells by
altering gut micro biota and modulating immune responses (Evans & Johnson, 2015).
Probiotic bacteria help reduce colonization of pathogenic organisms by competitively
inhibiting their adhesion on the intestinal mucosa surface (Kopp-Hooliahn, 2001).
A wide variety of probiotic species are available, but the most investigated are
species of

Lactobacillus (L acidophilus, L rhamnosus, L bulgaricus, L reuteri, L

casei) and Bifidobacterium. In the United States, probiotics are available primarily as
dietary supplements in capsule, tablet or powder formations. In addition, probiotics
occur in yogurt, sauerkraut, and other fermented foods (Heiberger, Hellwig & Ladwig,
2014).
Most studies evaluating probiotics in the prevention and/or treatment of C.
difficile have evaluated the yeast Saccharomyces boulardii (Florastor) and the bacteria,
Lactobacillus (Katz, 2005). The two most popular and studied probiotic organisms are
Lactobacillus and Bifidobacterium species (Pattani, Palda, Hwang, & Shah, 2013). An
important consideration is that the effects of any bacteria are strain specific, meaning the
data from research relates only to that specific strain. Research results cannot be
generalized to other species or strains (Hickson, 2011). For example, L. rhamnosus GG is
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a specific bacterial strain which demonstrates a probiotic effect in the prevention of AAD
(McFarland, 2006). Other strains of L. rhamnosus species may not have this effect, and
likewise other species in the genus of Lactobacillus may not act as probiotics. This is
because, individual strains exhibit different specific characteristics, such as resistance to
gastric acid and bile, ability to colonize the mucosa, and antimicrobial activity (Jacobsen
et al., 1999).
It is generally agreed that a probiotic must be capable of colonizing the intestinal
tract to influence human health (Pattani et al., 2013). This requirement may disqualify
many of the stains currently used in fermented dairy products. There is reasonable
evidence to support the use of S. boulardii for the prevention of antibiotic-associated
diarrhea at a dose of 1 gm daily in hospitalized adults (Pattani et al.). Lactobacillus GG
(LGG) is one of the most extensively studied probiotics which has proved to be beneficial
in reducing the severity and duration of antibiotic associated diarrhea (Kaur, Chopra, &
Saina, 2001). When consumed in a dairy product or as a lyophilized powder, LGG
colonizes the gastrointestinal track for 1-3 days in most individuals. The purported
benefits for any probiotic must pass the highest standards of scientific scrutiny before the
claims for its usefulness ca be accepted. In 2002 the World Health Organization (WHO)
and Food and Agriculture Organization (FAO) of the United Nations issued guidelines
detailing criteria that need to be fulfilled by a food product before labeling it as a
probiotic (Cordina, Shaikh, Shrestha, & Camilleri-Brennan, 2011). The guidelines also
detail what information should be available on the product label. These include genus,
species and strain designation, minimum viable numbers of each strain at the end of
shelf-life, suggested daily intake to achieve effective dose for claimed health benefits,
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health claims (which should be backed by scientific evidence) and recommended storage
conditions (Cordina, et al.).
Probiotics: Usage as a Preventative Measure of CDI
Most infection control strategies place emphasis on interruption of horizontal
transmission of C. difficile between patients, their environment, and healthcare workers.
Despite the fact that the use of probiotics for prevention of primary CDI is still not
identified as a core CDC recommendation, further improvements in the prevention of
CDI would benefit if focused on prevention of disease in those patients who are at risk
(Dubberek et al.,2014). The goal of therapy when using probiotics as a preventative
measure is to mitigate the effects of microbiota disruption. This approach involves the
introduction of competing, nonpathogenic (probiotic) organisms into the intestinal tract to
restore microbial balance (Pochapin, 2000). The theoretical premise behind this approach
is that the protective intestinal microflora is damaged by antibiotic treatment; the initial
antibiotic exposure thus leaves the host susceptible to colonization and subsequent
infection by Clostridium difficile (Pochapin, 2000). The current CDC core
recommendations for prevention include implementing an antimicrobial stewardship
program, contact precautions for duration of diarrhea, hand hygiene in compliance with
CDC/World Health Organization standards, cleaning and disinfecting the environment
and equipment, CDI education for all staff/personnel who come in contact with patients,
and laboratory based alert systems for immediate reporting of positive results (Dubberek,
et al,).
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In 2011, Avadhani and Miley published a meta-analysis with the purpose to report
findings from available studies that evaluate the efficacy of probiotics administered to
hospitalized adults in the prevention of antibiotic associated diarrhea (AAD) and CDI. A
comprehensive systematic search was conducted to identify all relevant studies on
probiotic efficacy in prevention of AAD and CDI. Data synthesis was done using
MAStARI software from the Joanna Briggs Institute in Australia (Avadhani & Miley,
2011). Results revealed that administration of probiotics led to a statistically significant
relative risk reduction of 71% for CDI which supports the potential role of probiotics to
favorably influence the mechanisms that is responsible for antibiotic associated diarrhea
and possibly CDI.
In 2013, Maziade, Pereira, & Goldstein published an observational study in the
Journal of Clinical Infectious Diseases. This study took place over a 10-year period,
beginning in 2004 and ending in 2015. In 2003 a 284- bed community hospital named
Pierre-Le Gardeur (PLGH) in Quebec Canada experienced a major outbreak of CDI.
They recognized that hospitals in metropolitan Montreal and the surrounding Quebec
region also had a marked increase in the incidence of CDI from 5.7 cases per 1000
patient admissions in 2001 to 28.2 CDI cases per 1000 admissions in 2003. After an
initial 6-month observational period that showed apparent ineffectiveness of the current
standard preventative measures (SPM) alone at PLGH, they added a probiotic bundle.
Beginning in January 2004 every inpatient adult on antibiotics (without any exclusion)
was started on a probiotic called BioK+ (combination of Lactobacillus acidophilus CL
1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2) within 12 hours
of the antibiotic prescription. Subjects were given 2 capsules per day each100 billion
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CFU (colony forming unit) and the probiotic was continued for five days’ post antibiotic
discontinuation. During the 10 years of observation, 44,835 inpatients received Bio K+.
During the combined observational phase (April 2005- March 2014) data was
published annually and were expressed as cases per 10,000 patient days. The average
annual incidence rate of CDI at PLGH remained at values much lower than those
observed in the conglomerate of other Quebec network hospitals (2.3 vs 7.5 cases per
10,000 patient- days). These values were also lower than those from equivalent hospitals
(> 250 beds) (8.3 cases per 10,000 patient-days). All rate reductions observed during the
initial utilization of Bio K+ were maintained for 9 years. The CDI rate at PLGH declined
from 19.0 cases per 10,000 patient days and remained at low mean levels of 2.3 cases per
10,000 patient days. This 10- year intervention resulted in a 73% reduction of CDI cases
(P<.001). Blood cultures were monitored a PLGH for Lactobacillus bacteremia through
the 10-year study, and no Lactobacillus bacteremia were detected.
This study did reveal that it was limited because it was an observational study as
opposed to a randomized control trail, and because it only studied one probiotic (Bio K+).
The study was sponsored by Bio K+ Plus International which may present a potential
conflict of interest.
In 2013 a systematic review and meta-analysis was published by Pattani et al. to
evaluate the efficacy of co-administration of probiotics with antibiotics in preventing
CDI. Systematic searches of MEDLINE, Embase, and the Cochrane Central Register of
Controlled Trials were searched for randomized controlled trials, published in English, of
adult inpatients who were receiving antibiotics and who were randomly assigned to co-
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administration of probiotics, with or without the use of placebo. Pooled analyses revealed
significant reductions in Antibiotic Associated Diarrhea (AAD) (RR 0.61, 95% CI 0.47 to
0.79) and CDI (RR 0.37, 95% CI 0.22 to 0.61) among patients randomly assigned to coadministration of probiotics. With subgroup analysis, significant reductions in rates of
both AAD and CDI were retained in the subgroups of good-quality trials and the trials
assessing a primarily Lactobacillus-based probiotic formulation. The interpretation made
from this meta-analysis and systematic review was that probiotics used concurrently with
antibiotics reduce the occurrence of AAD and CDI (Pattani et al.).
Fluoroquinolones and CDI
The CDC has identified antimicrobial use as one of the main modifiable risk
factors of CDI (Chernak et al, 2005). Virtually every antibiotic has been associated with
CDI although, for the past 10 years, fluoroquinolones, which were previously
infrequently associated with CDI, have been found to be one of the primary precipitating
antimicrobials (Dhalla & Mamandi 2006).
Yip, Loeb, Salama, Moss, & Olde (2001) published a case control study in the
Journal of Infection Control and Hospital Epidemiology. The study took place in a 300
bed tertiary-care hospital. All adult inpatient charts were reviewed during October 1998
to December 1998 to detect individuals with a positive enzyme immunoassay for C
difficile toxin. Twenty-seven patients were identified as subjects in the study. Casepatients identified with nosocomial CDI over the study period were compared with two
sets of control patients. When case-patients were matched to control patients by date of
admission, age, gender, and inpatient unit, the only significant risk factor in univariate
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analysis was prior use of Ciprofloxacin (odds ratio [OR], 5.5; 95% confidence interval
[CI95], 1.2–24.8; P=.03). Additionally, the following variables were entered into the
conditional logistic regression model: renal insufficiency, use of cephalosporins, use of
ciprofloxacin, and use of proton pump inhibitors. Use of ciprofloxacin was the only
variable that remained significant in the final model. This study found that patients with
CDI were at least five times more likely to have been exposed to ciprofloxacin than
control patients (OR, 5.5 and 9.5 for the first and second sets of control patients,
respectively). The authors of this study concluded that these findings raise concern about
the use of quinolones in acute-care hospitals with endemic CDI.
McCusker, Harris, Perencevich, and Roghmann (2003) performed a case control
study to evaluate the association between antibiotic use and CDI. The study was
performed in a 778 bed Veterans Administration hospital in Maryland over a six-month
period. Thirty patients who had their first occurrence of CDI were identified as subjects.
All 30 patients had documentation of receiving antibiotics within six weeks prior to the
positive CDI lab assay. Matched univariate analysis of risk factors for CDI showed that
fluoroquinolone use odds ratio [Odds ratio] 13.5; 95% confidence intervals [CI] 3.1 to
58.8) and clindamycin use (OR 3.1; 95% CI 1.0 to 9.4) were associated with developing
CDI. A multivariable regression style showed that treatment with Fluoroquinolones
(odds ratio 12.7, 95%, confidence interval (CI) 2.6-61.6) was the strongest risk factor for
CDI.
Sarma, Marshall, Cleeve, Tate, Oswald, and Woolfrey (2015) published
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an interrupted time-series analysis pre and post fluoroquinolone restriction for 60 months
based on a Poisson distribution model. The primary aim of this study was to describe the
implementation and to analyze the impact of fluoroquinolone restriction on CDI over a
five-year period (2007–08 to 2011–12) in two hospitals. Approximately 93% of cases
received antibiotics within the eight weeks prior to infection and the majority received
either cephalosporins (52%) or fluoroquinolones (41%).
Findings suggested that in June 2008, fluoroquinolone consumption decreased in
half to about 5 defined daily doses (DDD) per 100 occupied bed –days (OBD). This was
followed by a significant fall in CDI rate (rate ratio 0.332, 95% CI: 0.240-0.460) which
remained low over the subsequent months. Fluoroquinolone consumption was further
reduced to about 2 DDD/100 OBD in June 2010, accompanied by further reduction in
CDI rate (rate ratio: 0.394; 95%CI,: 0.199- 0.781). The researchers concluded that the
reduction in fluoroquinolone usage was associated with an immediate, large, and
significant reduction in CDI cases.
Prescribers Influence
Health care providers prescribe 258 million courses of antibiotics, which
translates to 833 prescriptions per 1000 people, or four out of five people (Hicks &
Taylor, 2013). While antibiotic-prescribing rates declined in the 1990s, there has been a
steady increase in their use since then (Ashiru-Oredope, Sharland, Charani, McNulty, &
Cooke, 2012).
To be qualified to prescribe medications, prescribers are required to undergo the
necessary training to achieve a solid understanding of antibiotic pharmacotherapeutics
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(Hicks & Taylor, 2013). Not only must the prescriber possess confidence in their
prescribing methods but they must also know the risk vs. benefit of prescribing such
medication. The ability to properly prescribe medication to treat disease is a major factor
in the establishment of a trusting rapport with patients. Accordingly, patients must have
faith in their prescriber’s ability to accurately and safely prescribe medications. To
remain effectively integrated in their patients' care, health care providers must consider
the risk for development of CDI from antibiotic use and be familiar with common beliefs
about probiotics while be prepared to discuss probiotics with patients who express an
interest in pursuing these options.
One of the first studies to directly assess practicing physicians' perceptions on the
efficacy, use, and practice patterns for recommending probiotics in the treatment of
gastrointestinal disorders was by Williams, Ha and Ciorba (2010). The objective of this
study was to determine how gastroenterologists perceive and use probiotic-based
therapies in practice. A 16 item multiple choice questionnaire was developed and
distributed to practicing gastroenterologists and physicians in Saint Louis, Missouri.
Participants specialized in gastrointestinal disorders and were from both private
community based gastroenterology practices as well as academic affiliates of two
medical schools. A total of 96 invitations were sent, 56 (58%) physicians completed the
survey with a response rate of 65% among academic-based physicians and 53% of
community practice physicians (P=0.30). Twelve responses came from continuing
medical education participants including 7 primary care physicians, 1 community
gastrointestinal surgeon, and 4 senior fellows. Results showed that all the private
practitioners surveyed described themselves as, “somewhat familiar with the literature
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involving probiotics”, and considered them safe. Additionally, 98% (n = 56) expressed a
belief that probiotics had a role in the treatment of GI illness and symptoms (Williams et
al., 2010).
Similarly, 98% of the surveyed physicians recommended probiotics for irritable
bowel syndrome, Clostridium difficile-associated diarrhea and for patients during
antibiotic use; because they believed that the literature supports their usage for these
conditions. Of all the respondents n= 56 both private practice physicians and academic
were most familiar with the individual probiotic preparations B. infantis (Align) 89% and
93% the commercially sold yogurt-based probiotic supplement preparations known as
Danative, Yakult, and Lifeway. However, a majority of them were also familiar with
Lactobacillus rhamnosus GG (Culturelle) 61% private practice physician and 42%
academic medicine physician n= 56 and Florastor (Saccharaomyces boulardii) 71%
private practice physician and 39% in academic medicine physician n= 56. Both private
and academic practitioners had similarly positive responses regarding the efficacy of
probiotics. Despite their tendency to prescribe the probiotics, results showed that 82%
n=56 of the surveyed physicians reported that probiotics were “sometimes” effective, 7%
n=56 responded that they were “always” effective, and 11% n=56 of physicians had
never recommended probiotics in their practice. In this survey, patients seen by private
practitioners more commonly took probiotics for C. difficile-associated diarrhea when
compared with patients of their academic counterparts, 89% versus 55%. Conditions for
which physicians believe literature supports probiotic usage included irritable bowel
disease, antibiotics associated diarrhea, clostridium difficile, pouchitis, ulcerative colitis
and crohn’s (Williams et al. 2010).
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A study by Cordina, et al. (2011) aimed to investigate the current attitudes and
prescribing practices of surgeons and gastroenterologists related to probiotics in the
treatment of gastrointestinal disorders. A questionnaire was designed to examine the
frequency of probiotic prescribing, types of probiotics used, indications for and duration
of treatment and clinicians' experiences with probiotic use. A total of 220 questionnaires
were mailed to consultant gastroenterologists and surgeons practicing in the United
Kingdom. A total of 177 respondents, of whom 73 were surgical consultants and 104
were gastroenterologists. The response rate was therefore 73.0% for surgical consultants
and 86.7% for gastroenterologists (P = 0.016) with an overall response rate of 80.5%. Of
the surgical consultants who responded, 26 (35.6%) were colorectal surgeons, 16 (21.9%)
upper GI surgeons, and 31 (42.5%) were general surgeons.
Overall, 123 of the 177 respondents (69.5%) recommended or prescribed
probiotics to their patients. A total of 80.8% gastroenterologists (84 of 104)
recommended or prescribed probiotics to their patients and only 53.4% (39 of 73) of
consultant surgeons did so (P = 0.00013). When comparing the different surgical
specialties, probiotics were more commonly prescribed by colorectal surgeons, of whom
88.5% (23 of 26) said they prescribed or recommended probiotics to their patients,
compared to only 43.8% (7 of 16) of upper GI surgeons and 29.0% (9 of 31) of general
surgeons (Cordina et al,2011). Of the respondents, 15.4% indicated prescribing for the
treatment or prevention of Clostridium difficile-associated diarrhea (CDAD) and 5.1%
prescribed for indication of antibiotic- associated diarrhea.
Information published specifically related to nurse practitioners (NPs) and
probiotics is minimal. In the August 2015 Gastric Health edition of the Journal of Nurse
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Practitioner Avadhani and Steefel (2012) published a review that sought to educate nurse
practitioners on the use and benefits of probiotics. This article reinforced the
accountability that nurse practitioners share along with their physician’s colleagues in
their role regarding the use of probiotics. Amidst increasing information of probiotics,
understanding the use and purpose of probiotics is still a source of confusion for the
average consumer. Probiotics are readily available over the counter (OTC) and can be
purchased in capsule, tablet, powder forms, or in yogurt. Advertisers promote the
advantages of probiotics without a full explanation of the product. Nurse Practitioners
should be educated the basics of probiotics, criteria for patient use, considerations
regarding affordability of the medication and whether use of a probiotic will fit into the
patient’s lifestyle. Avadhani and Steefel, 2012 also emphasized the importance of NPs
having knowledge of various strains of probiotics, especially the most common strains, as
the benefits of one strain may not hold true to other strains and the suitability of
probiotics for their patient may be impacted by the various strains. Knowledge of these
factors is important for an NP’s prescriptive advice.
The theoretical framework which guided this study will be discussed next.
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Theoretical Framework
The American Association of Colleges of Nursing (AACN) Synergy Model was
chosen to guide the framework of this research. The AACN Synergy Model for Patient
Care was developed to link clinical practice with patient outcomes. This model
incorporates what the patient expects, what the health care professional should provide,
and what the health care system should deliver. Additionally, the framework also
supports that optimal outcomes result from the synergy of nurses’ competencies and the
nurses’ ability to meet the needs of patients, their families, and the system (Kaplow &
Hardin, 2004).
This model incorporates patient characteristics including, predictability, and
complexity, risk of death, vulnerability, and participation in care. While conducting this
research these patient characteristics helped to guide and direct the focus and intentions
of the study. For instance, it is reasonable to assume, that the majority of hospitalized
patients expect that to receive optimal care and be healed as opposed to gaining
additional medical problems while being cared for in the hospital. This concept aligns
with the synergy model’s components of patient expectations.
Vulnerability, is the patient’s level of susceptibility to actual or potential stressors
that may or may not adversely affect the patient outcomes (Kaplow & Hardin, 2004). As
stated earlier the CDC (2015 a) projects that more than half the patients in a hospital are
receiving antibiotics which translates to a large population who are vulnerable.
Predictability, allows us to expect or anticipate a certain course of events.
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The Synergy Model also incorporates nurse characteristics including clinical
judgment, advocacy, collaboration, and system thinking (Kaplow & Hardin, 2004). These
characteristics were particularly pertinent to this research study. All of these
characteristics embody the responsibility and impact that nurses and/or providers have in
utilizing all of the existing preventative measures for the development of CDI. Clinical
judgment speaks to the health care professional’s ability to recognize individuals who are
at risk for CDI as well as their knowledge base as to what makes a risk factor a risk
factor. Additionally, collaboration and system thinking are two vital components of this
model that pertained to the core themes of this research study (Kaplow & Hardin, 2004).
Prevention of CDI in many ways betters the system within the hospital as well as
promotes health outside the hospital doors. For that reason, CDI acquired infections are
tracked by the individual inpatient unit and hospital, but is also tracked by each state
department of health and extends all the way to the CDC for national tracking. As a
result, CDI prevention is the responsibility of more than just the nurse or the provider, but
rather it’s the responsibility of the whole system.
The Synergy Model that can also guide nursing research and care across multiple
clinical populations (Kaplow & Hardin, 2004). The Synergy Model has guided this study
by utilizing the concept of meeting patient needs and influencing patient outcomes. With
this model as a guide, the research results have helped to provide insight into how nurses
and licensed independent practitioners can advocate for their patients by considering the
additional preventative measures of probiotic in prevention of hospital acquired CDI.
The methods guiding this study will be presented in the next section.
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Method
Purpose
The purpose of this research was to explore healthcare providers prescribing trends
regarding Fluoroquinolone antibiotics and adjunctive probiotics in patients with hospital
acquired CDI.
Design
This study was a descriptive retrospective chart review of patients admitted from the
time frame of March 29, 2015 to January 31, 2016. Patient records with a discharge
diagnosis of hospital acquired CDI during that time period were reviewed.
Sample and Site
Inclusion criteria included records of both male and female individuals 18 years of
age and older who received care as inpatients at The Miriam Hospital, a 247- bed acute
care, university affiliated teaching hospital located in Providence, Rhode Island. All
participants needed to have been diagnosed with hospital acquired clostridium difficile
via ICD 9 and 10 (International Classification of Disease) during their hospital stay at the
study site. Exclusion criteria included records of patients who were admitted with a
previous diagnosis of CDI or were admitted to rule out a community acquired CDI.
Procedure
Permission was obtained from the Chief Nursing Officer of TMH as well as the
director of Infection Control at TMH. The Lifespan and RIC IRBs reviewed and
approved this study. Data for this research were obtained through a retrospective chart
review conducted at The Miriam Hospital (TMH). Participants with hospital acquired
CDI were identified under the guidance of the institution’s Department of Infection
Control through a tracking system called Theradoc. The researcher was provided access
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to electronic medical records upon IRB approval. Data for the specific participants who
were diagnosed with hospital acquired CDI between the dates of March 29, 2015 to
January 31st, 2016 were provided to the researcher by the Director of TMH Infection
Control department. The researcher then categorized charts based upon whether or not
the participants received an oral or intravenous Fluoroquinolone antibiotic and/or if they
were receiving a probiotic. Only data meeting the inclusion criteria and required for
analysis were extracted and no identifying information was collected.
Measurement
A worksheet (Appendix A) was developed by this researcher and was used to gather
the above information. The data collection tool was developed based on the review of the
literature, the identified variables of interest, and clinical experience.
Data Storage and Analysis
Data were stored on a Lifespan encrypted and approved USB zip drive and kept
with the researcher in a locked safe. After completion of the research, the USB zip drive
was locked in the primary investigator’s office.
Basic descriptive statistics was utilized to analyze and summarize the probiotic
prescribing trends of health care providers at this institution during the specified time
frame. Additionally, comparisons were made between the percentages of subjects who
developed CDI that were also on a fluoroquinolone antibiotic and those that were on a
prophylactic probiotic.
Next, study results will be presented.
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Results
A total of 96 records were reviewed; of those records, 16 were excluded for not
meeting inclusion criteria. The remaining 80 records met inclusion criteria (n= 80)
because subjects were given a diagnosis of hospital acquired clostridium difficile
infection between the dates of March 29, 2015 and January 31, 2016. Table 1 below
illustrates ….
Table 1 Core Data
Total number of hospital acquired (HA) CDI patients

n=80

Patients receiving fluoroquinolone when diagnosed with CDI

n=41 (53%)

Of the total CDI patients (80) those also receiving probiotics

n=22 (28%)

% of Fluoroquinolone receiving patients (41) also prescribed probiotic

55%

Of those 80 subjects, 53% (n= 41) were receiving a Fluoroquinolone antibiotic
when diagnosed with CDI and 22 (n= 28%) were prescribed a probiotic. Fifty-five
percent of the subjects who were prescribed a Fluoroquinolone (n= 41) were also
prescribed a probiotic. The most commonly prescribed Fluoroquinolone was
Ciprofloxacin (76%). A further breakdown of the types of Fluoroquinolones prescribed is
illustrated in Table 2.
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Table 2
Types of fluoroquinolones prescribed
Type of Fluoroquinolone

N = 41

# and % from the total who received a Fluoroquinolone (n= 41)

Ciprofloxacin

31/ 41

(76%)

Levaquin

8/ 41

(20%)

Moxifloxacin

2/41

(5%)

Florastor, an oral tablet which is also labeled as Saccharomyces boulardii was the
most commonly prescribed probiotic; accounting for 68% of the probiotics prescribed
(n=22). The two additional probiotics were shown to be less commonly prescribed. Table
3 illustrates the prescribed probiotics.
Table 3
Types of probiotics prescribed

n = 22

Type of Probiotic prescribed
Florastor 250mg two times daily

# and % that were prescribed (n=22)
15 / 22

( 68%)

Lactinex 1 package two times daily

4 / 22 ( 18%)

Culturelle (Acidophilus) 1-2 tablets daily

3 / 22 ( 14%)
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Of the 80 subjects, 28% (n= 22) were prescribed a probiotic at some point in their
hospital stay. In the institution studied, physicians constitute the majority of practitioners
and the number of physician assistants (PAs) and nurse practitioners (NPs) are about
equal. A review of prescribing trends specific to each credentialed prescriber is
illustrated in Table 4.

Table 4
Prescribers who prescribed probiotic
Prescriber Credentials

n = 22
# and % of probiotics prescribed (n=22)

Physician

12 / 22 (54%)

Nurse Practitioner

7 / 22 (32%)

Physician Assistant

3 / 22

(14%)

Of the 22 subjects prescribed a probiotic, 18% were prescribed prior to the
diagnosis of CDI. Thirty-six percent of the probiotics (n = 22) were prescribed at the time
of CDI diagnosis. A significant percentage (23%) of probiotics were prescribed one day
after CDI diagnosis; this may have been due to late diagnosis. A large percentage of
patients (81%) that were receiving probiotics while hospitalized did not continue
probiotic at time of discharge; this raises curiosity. What are the reasons for discontinuing
therapy and is this due to a lack of provider knowledge or confidence in prescribing
probiotic therapy? Table 5 illustrates timing of probiotics being initiated.
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Table 5
Initiation of Probiotic Therapy

n = 22

Time probiotics were initiated

# and % initiated at that time

Probiotic prescribed before CDI diagnosis

4 / 22

Probiotic prescribed at time of CDI diagnosis

8 / 22 (36%)

Probiotic prescribed one day after CDI diagnosis

5 / 22 (23%)

Probiotic prescribed at time of discharge

5 / 22 (23%)

Summary and conclusions will be presented next.

(18%)
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Summary and Conclusions
Nosocomial infections contribute as major causes of death and increased
morbidity among hospitalized patients and represent a significant burden to both the
patient and for public health. The advancing age of patients admitted to the hospital, the
greater prevalence of chronic diseases, the increased use of diagnostic procedures and
therapeutic medications all affect the host defenses and will contribute to the continuing
incidence of nosocomial infections in the future (World Health Organization, 2002).
There are a variety of factors which place a patient at risk for the development of hospital
acquired CDI, including decreased immunity, the increasing variety of medical
procedures and invasive techniques creating potential routes of infection, and the
transmission of drug-resistant bacteria among crowded hospital populations, where poor
infection control practices may facilitate transmission (Sehulster, 2010).
Clostridium difﬁcile now rivals methicillin-resistant staphylococcus aureus
(MRSA) as the most common pathogen to cause hospital acquired infections (HAI) in the
United States (Dubberke et al., 2014). Strategies to Prevent Clostridium Difficile
Infections in Acute Care Hospital, published by the Society for Healthcare Epidemiology
of America (2014) reported that patients who received ICD 9 codes for the discharge
diagnosis of clostridium difficile infection more than doubled from 2000 to 2009
(Dubberke et al.). An estimated half a million CDIs were reported in the United States in
2011 (CDC, 2015a). Approximately 83,000 of those patients experienced at least one
recurrence and 29,000 of them died within 30 days of the initial diagnosis (CDC, 2015a).
In a study by Williams et al., in 2010, 98% (n=56) of gastroenterologists expressed a
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belief that probiotics had a role in the treatment of GI illness and symptoms including
CDI.
A notable inconsistency in the prescribing of probiotics as an adjunctive therapy
to prevent hospital acquired CDI inspired the purpose of this research. A retrospective
chart review examined the prescribing trends for probiotics in patients hospitalized at The
Miriam Hospital in Providence Rhode Island from March 29, 2015- January 31st 2016.
The sample included records of patients who had been diagnosed with hospital acquired
CDI during that timeframe (n= 80). Descriptive statistics were performed; 53% (n= 41)
were receiving a Fluoroquinolone at the time CDI was diagnosed. Florastor
(Saccharomyces boulardii) was identified as the most commonly prescribed probiotic,
making up 68% of the probiotics prescribed to this population, with the second most
common being Lactinex (18%). Further analysis of the data was unable to identify a
strong association between CDI diagnosis and lack of early probiotic prescribing prior to
diagnosis. Of the 80 patients who developed hospital acquired CDI, only 18% (n= 22)
received probiotics early enough that it would be considered a preventative approach, yet
those 18% still acquired CDI.
Of the 80 patients diagnosed with hospital acquired CDI, over half (53%) were
receiving a Fluoroquinolone at the time of diagnosis, suggesting a potential association
between Fluoroquinolone use and the acquiring of CDI. Twenty-eight percent (n = ) of
the patients who developed hospital acquired CDI were receiving a probiotic and of those
prescribed a probiotic (n = 22), the majority were initiated at time that CDI was
diagnosed. Probiotics protect intestinal epithelial cells by altering gut micro biota and
modulating immune responses, reduce colonization of pathogenic organisms by
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inhibiting their adhesion to the in intestinal mucosa surface. Therefore, prescribing a
probiotic at time of CDI diagnosis is understandable yet it does not align with using
probiotics as a preventative measure. In order for probiotics to serve as an adjunctive
intervention in primary prevention of CDI, they must be prescribed prior to acquiring
CDI (Evans & Johnson, 2015). In this study, 18% (n=22) were prescribed prior to CDI
diagnosis and that the majority of probiotics (46%; n =22) were prescribed after CDI
diagnosis, with all of those subjects still developed CDI.
The development of CDI is multifactorial in that many variables s can contribute
to its development. Some of those factors include, but are not limited to, poor infection
control measures, immunocompromised health state, alerted or impaired gastrointestinal
health, the age of the patient (very young and very old at greater risk), long term/chronic
antibiotic, proton pump inhibitor or chemotherapy use (World Health Organization,
2002). It cannot be concluded that the development of CDI is solely due to a lack of
probiotic use.
The limitations in this study included that the researcher did not consider certain
subject characteristics that could be key factors in the development of CDI, including the
state of health, age, past medical history and institutional factors (such as cleanliness,
outbreaks, or infection control measures). Also, the inclusion criteria included only the
comparison of probiotics to Fluoroquinolones and did not compare any other class of
antibiotics. The study was also limited by the relatively small sample size and the
retrospective nature of the study. The results of this study illustrated that prescribing
probiotics at the initiation of antibiotic therapy was not a common practice among
physicians, nurse practitioners, and physician assistants at this institution. Only 28% of
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patients (n= 80) were prescribed a probiotic during their hospitalization. Overall
prescribing patterns around the use of probiotics are inconsistent. Nurse practitioner
prescribers were for the most part equal contributors in the prescribing of probiotics.
Recommendations and implications for advanced practice will be presented next.
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Recommendations and Implications for Advanced Nursing Practice

As the field of probiotics continues to expand in the United States, so does the
need for practitioners to be aware of probiotic use. Amidst increasing information about
probiotics, prescribers’ and consumers’ understanding of use and indications remains a
source of confusion. Probiotics are readily available over the counter (OTC) and can be
purchased in capsule, tablet, powder, and yogurt. Advertisers promote the advantages of
probiotics without a full explanation of the product. Advanced practice nurses should be
educated on the basics of probiotics as well as their indications for use. Advanced
practice nurses should also be familiar with the various strains of probiotics, the most
common strains, and that the benefits of one strain may not hold true to other strains.
Knowing this is important for an advanced practice nurses’ prescriptive advice. Based
on the results of the above study, nurse practitioners were for the most part equal
contributors in the prescribing of probiotics. This is encouraging, yet, the fact that such a
large percentage of patients that were not continued on their probiotic at time of
discharge raises curiosity. What are the reasons for discontinuing therapy and is this due
to a lack of knowledge or confidence in probiotic therapy? A recommendation for
institutions is to consider incorporating annual education for all clinicians regarding the
detrimental downstream effects of overprescribing antibiotic and under prescribing
probiotics.
To aid in providing the best patient care, advanced practice nurses should be
cognizant of the fact that hospital-acquired infections such a CDI can lead to functional
disability, emotional stress, and disabling conditions that reduce a patient’s quality of life.
Additionally, the economic costs attached to such infections is demanding to an
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institution. Hospital acquired infections such as CDI can increase patient length of stay,
limit hospital reimbursement, and injures the hospital’s infection rate. All of these
factors can negatively impact a hospital’s ability to receive/renew licensure,
accreditations and meeting certain standards for delivery of care and safety. As advanced
practice nurses who are incorporating system measures into their practice, hospital
acquired infections such as CDI can carry a magnitude of implications. Considering
adjunctive therapy such as probiotics that can help reduce the risk of CDI is a
responsibility each practitioner holds with their license to practice.
The lack of strong evidence-based research studies to support the use of probiotics
in CDI prevention is a contributing factor to its failed adoption into practice. Policy
change often stems from large, well-known, published studies sponsored by
pharmaceutical companies and /or institutions that gain acknowledgment and
consideration by the medical community. Although studies supporting the incorporation
of probiotic therapy in the prevention of CDI remains scarce, the evidence that does
exists has potential for expanded use. Momentum has been made but lack of firm
scientific evidence truly supports the need for further research. Such research could be a
collaborative effort amongst multiple disciplinarians such as advanced practice nurses,
pharmacy and infection control. This multi-disciplinary approach could maximize the
study’s potential and influence policy change.
Institutions should consider adding probiotic therapy to CDI prevention bundles.
Include probiotic therapy along with the already implemented CDI prevention tools; such
as hand hygiene, staff education, contact precautions, disinfection of spores. The
institution in which the data for this study was collected, does not currently support the
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use of probiotic therapy in the prevention of CDI. It would be recommended that this
institution consider adding probiotic therapy to their already existing CDI prevention
bundle and collect data to see if it’s incorporation produces a reduction in hospital
acquired CDI rates. As suggested above, collaborative efforts among multidisciplinarians such as advanced practice nurses, pharmacy and infection control would
make the most impact. This multi-disciplinary group should work with the institution’s
providers to identify and explore the barriers to the use of probiotics.
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Appendix A
DATA POINTS

REVIEW OF PATIENT RECORD
1

Day of hospitalization that
CDI was acquired
Was a Fluroquinolone
prescribed?
If yes, which Fluroquinolone
was prescribed?
Hospital day that
Fluroquinolone was
prescribed.
Was a probiotic prescribed?
Hospital day that probiotic
was initiated?
Which probiotic was
ordered?
Probiotic was ordered by
APRN, PA, or MD

2

3

4

5

6

7

8

9

